Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesWound CareSelect Health skin substitutes Coverage & Prior Au…
    Ask Trek AI about this page
    Currentselect_healthPolicy CCP. 1552

    Skin Substitutes for Chronic Wounds

    Customize your policy alerts

    Sign up for select_health Policy CCP. 1552 alerts

    Get alerted when Policy CCP. 1552 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage policy for the use of cellular and acellular skin substitute products for cutaneous wounds and thermal burns, describing medical necessity criteria, limitations, and supporting evidence for providers and claims reviewers.

    Policy Summary
    Payerselect_health
    PolicySkin Substitutes for Chronic Wounds
    Policy CodePolicy CCP. 1552
    Change TypeNo material changes
    Effective DateNov 1, 2025
    Last ReviewNov 1, 2025
    Next Review DateMar 1, 2027
    Key ActionObtain prior authorization documenting a prepared wound bed, absence of active infection, objective perfusion assessment, evidence of optimized standard care, and product-label–consistent selection and duration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥50% at 4wResponse threshold
    >30 mmHg toe / TcPO2>25Perfusion thresholds
    2.9DFU healing OR
    86%Burn graft take

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    DFU / VLU / burns
    Applies to
    4 weeksReassessment interval

    Coverage Criteria for Skin Substitutes

    inv-01: General (all indications)

    Covered when ALL of the following are met:

    General criteria: Partial or full-thickness cutaneous defect with a prepared wound bed (adequate debridement, clean, moisture-balanced) and no clinical signs of active infection; managing the specific cause of the wound during treatment (e.g., proven offloading for diabetic foot ulcers or sustained compression for venous leg ulcers); nutritional status assessed and optimized; objective perfusion assessment supports healing potential as defined for the indication; one product used at a time; no known hypersensitivity to the product source; application technique and frequency conform to the FDA-labeled instructions for the selected product.

    inv-02: Diabetic foot ulcers (neuropathic, non-ischemic)

    Covered when ALL of the following are met:

    Perfusion: Adequate perfusion documented by any of: toe pressure >30 mm Hg, skin perfusion pressure >40 mm Hg, or transcutaneous oxygen pressure >25 mm Hg. Urgent vascular imaging and consultation for revascularization must be considered if ankle pressure <50 mm Hg, ankle-brachial index <0.5, toe pressure <30 mm Hg, or transcutaneous oxygen pressure <25 mm Hg. Ankle-brachial index alone is unreliable in diabetes.
    Wound characteristics and prior care: Chronic, non-infected ulcer extending through the dermis without exposed tendon, muscle, capsule, or bone; failed to show >50% area reduction after >4 weeks of optimized standard care (serial debridement, moisture balance, infection control, and effective offloading). Wound must meet product labeling minimum chronicity (e.g., >3 weeks for Apligraf; >6 weeks for Dermagraft).
    Other: Glycemic management being addressed/optimized; no untreated osteomyelitis at the ulcer site and no active Charcot process involving the ulcer surface.

    Manage infection or Charcot before applying a skin substitute.

    inv-03: Nonhealing dermal wounds (non-pressure)

    Covered when ALL of the following are met:

    Perfusion: Adequate perfusion documented by any of: toe pressure >30 mm Hg, skin perfusion pressure >40 mm Hg, or transcutaneous oxygen pressure >25 mm Hg. Urgent vascular imaging and consultation for revascularization must be considered if ankle pressure <50 mm Hg, ankle-brachial index <0.5, toe pressure <30 mm Hg, or transcutaneous oxygen pressure <25 mm Hg. Ankle-brachial index alone may be unreliable in diabetes.
    Wound failure: Non-infected, partial- or full-thickness traumatic, postsurgical, or ischemic/venous-mixed ulcers that fail to improve after >4 weeks of optimized standard care; selection should follow product labeling and objective monitoring.

    inv-04: Venous leg ulcers

    Covered when ALL of the following are met:

    Perfusion and compression: Adequate arterial perfusion confirmed: apply standard compression if ankle-brachial index >0.8; consider modified/light compression if ankle-brachial index 0.5–0.8; do not initiate compression if ankle-brachial index <0.5 or >1.3. Sustained therapeutic compression must continue during treatment.
    Wound failure: Chronic, non-infected partial- or full-thickness ulcer that has failed to show meaningful improvement (e.g., <50% area reduction) after >4 weeks of optimized standard care with sustained therapeutic compression, appropriate debridement, infection control, and moisture balance.

    inv-05: Thermal burns

    Covered when ALL of the following are met:

    Burn indications: Partial- or deep partial-thickness thermal burns that have undergone appropriate excision and hemostasis; no burn wound infection present; autograft not immediately available or is being staged; products used for temporary coverage, donor-site optimization, or to reduce autograft burden per product labeling and evidence.

    inv-06: Coverage with criteria

    Covered when aligned with FDA labeling and the policy's regulatory-verified appendix for the relevant wound type

    Core requirements: 1) Wound is a diabetic foot ulcer, venous leg ulcer, or thermal burn addressed by the appendix; 2) Product selection is consistent with FDA labeling and the regulatory-verified framework; 3) Appropriate prior conservative therapy and clinical documentation are provided.

    Derived from appendix purpose and policy framing

    inv-07: General coverage criteria for skin substitutes

    Covered when ALL of the following are met

    FDA-labeled indication match: Product selection must exactly match the FDA-labeled indication (etiology, depth, duration, anatomic limits, population).

    See product-specific minimum durations and anatomic limits in quick-reference tables.

    Foundational care optimized: For diabetic foot ulcers: evidence-based offloading and infection control; for venous leg ulcers: sustained therapeutic compression; for all wounds: adequate perfusion, debridement as needed, moisture balance, and infection management.

    Documented prior to advanced product use.

    Minimum wound duration met: Minimum duration before advanced therapy per product labeling (e.g., Apligraf DFU ≥3 weeks; Dermagraft/Omnigraft DFU ≥6 weeks; VLU Apligraf >1 month with compression).

    Some FDA labels may require longer durations.

    Use of skin substitute products is considered investigational/not medically necessary when required elements of optimized, etiology-specific conservative care are not documented. Examples that may justify denial include lack of documented offloading for diabetic foot ulcers or lack of sustained therapeutic compression for venous leg ulcers, an unprepared wound bed or uncontrolled infection, untreated ischemia below defined perfusion thresholds, known hypersensitivity to the product source, active systemic conditions (e.g., vasculitides) that require primary medical management, prophylactic or cosmetic use on intact skin, use on fully epithelialized wounds, simultaneous application of more than one product to the same wound, or continued use when there is less than 50% area reduction after 4 weeks of product use.

    Coverage is contingent on alignment with FDA labeling and the policy’s regulatory-verified product selection framework in the appendix. Use of a skin substitute outside FDA-labeled indications or in a manner inconsistent with the appendix-based framework may be excluded from coverage and is therefore investigational or not medically necessary.

    Ulcers that expose deep structures (tendon, muscle, joint capsule, or bone) are not eligible for the listed skin substitute products unless the specific product labeling explicitly permits use for wounds with exposed structures. Surgical management or other appropriate coverage should be optimized before considering a skin substitute in these cases.

    Routine or prophylactic use of skin substitutes for pressure ulcers is not supported by current evidence and is considered not medically necessary. Guideline summaries note limited and inconsistent data for pressure ulcer indications, and recommend foundational measures (perfusion, infection control, optimized standard care) before any advanced therapy is attempted.

    Comparative-effectiveness evidence does not demonstrate a universal superiority of cellular over acellular skin substitute products across wound types. Head-to-head trials show varied outcomes and context-dependent differences; therefore selecting a more complex or costly cellular product as the sole option requires justification based on FDA labeling, the regulatory framework, or specific comparative evidence rather than presumptive superiority.

    When advanced therapy is initiated, the policy requires objective reassessment at four weeks. Continuation of a skin substitute beyond four weeks is not medically necessary unless the wound area has decreased by at least 50% at the 4-week reassessment. If this response threshold is not met, providers should stop the product, reassess the treatment plan, and consider alternative approaches in accordance with labeling and the decision framework.

    Regulatory Identifiers, Codes, and Clinical Thresholds

    Regulatory product identifiers citedmixed
    P950032/S016Apligraf diabetic foot ulcer PMA (May 22, 1998)
    P000036Dermagraft PMA (Sep 28, 2001)
    P900033/S042Omnigraft PMA (Jan 7, 2016)
    K061711OASIS 510(k) (Jul 19, 2006)
    K132343Kerecis 510(k) (Oct 23, 2013)
    STN 125730StrataGraft BLA (Jun 15, date in table)
    BP170122RECELL Autologous Cell Harvesting Device PMA (Sep 20, 2018)
    H990002Epicel HDE (Oct 25, 2007)
    K242146Biobrane 510(k) (Dec 17, year partial)
    K090160Suprathel 510(k) (May 20, 2009)
    Perfusion thresholds — Toe pressure, SPP, TcPO2, ABI considerations
    Toe pressure> 30 mm Hg indicates adequate perfusion; toe pressure < 30 mm Hg prompts urgent vascular imaging/consultation.
    Skin perfusion pressure (SPP)>= 40 mm Hg supports healing potential.
    Transcutaneous oxygen pressure (TcPO2)>= 25 mm Hg supports healing potential; TcPO2 < 25 mm Hg prompts urgent vascular imaging/consultation.
    Ankle‑brachial index (ABI) considerationsABI may be unreliable in diabetes; use ABI thresholds to guide compression: >0.8 = standard compression, 0.5–0.8 = modified/light compression, <0.5 or >1.3 = do not initiate compression and consider vascular evaluation.
    Response threshold — Failure to achieve ≥50% wound area reduction after >4 weeks of optimized standard care

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Confirm general and indication‑specific criteria via prior authorization

    Prior authorization must confirm that all general criteria and indication-specific criteria are met before coverage is authorized — including a prepared wound bed (adequate debridement, clean, moisture-balanced), no clinical signs of active infection, objective perfusion assessment, and evidence that etiology-specific management (e.g., offloading for DFU or sustained compression for VLU) is in place. The application technique and frequency must conform to the FDA-labeled instructions for the selected product.

    • Prepared wound bed: adequate debridement, clean, moisture-balanced; no clinical signs of active infection.
    • Etiology-specific management documented: proven offloading for diabetic foot ulcers or sustained compression for venous leg ulcers.
    • Objective perfusion assessment documented as appropriate for indication.
    Prior Authorization

    Expect prior authorization tied to FDA‑label alignment and appendix framework

    Prior authorization is expected whenever payer decision rules require alignment with FDA labeling and the regulatory‑verified appendix framework (product‑to‑wound mapping and tier rules); submitters should expect review against the appendix rules for diabetic foot ulcers, venous leg ulcers, and thermal burns.

    Clinical Background and Rationale

    Chronic wounds are wounds that persist beyond the expected initial healing period (commonly defined as >4–6 weeks) and frequently fail to reduce in size despite optimized standard care. These wounds carry increased risks including local infection, progression to deeper tissue involvement, osteomyelitis, limb loss, and higher mortality. Advanced products—cellular or acellular skin substitutes—offer scaffolds, barrier function, and biologic factors to support repair, but they are intended as escalation therapies only after foundational measures (adequate perfusion, infection control, debridement, and etiology-specific management such as offloading or compression) have been applied and documented.

    Definitions and Regulatory Terms

    Skin substitute — cellular vs acellular definition and sources
    Cellular skin substituteContains living cells or cell-derived components (e.g., bilayer constructs, cultured skin) often intended to replace dermal and/or epidermal layers.
    Acellular skin substituteDecellularized matrices or membranes without living cells (e.g., placental membranes, xenografts, synthetic polymers) that provide scaffold and biologic milieu.
    SourcesHuman (autologous or allogeneic), non-human (xenographic such as porcine or bovine), synthetic polymers, or biosynthetic composites.
    Prepared wound bed — adequate debridement, moisture balance, no active infection
    DebridementAdequate debridement of nonviable tissue and biofilm is required prior to applying a skin substitute.
    Moisture balance
    Policy Summary
    Payerselect_health
    PolicySkin Substitutes for Chronic Wounds
    Policy CodePolicy CCP. 1552
    Change TypeNo material changes
    Effective DateNov 1, 2025
    Last ReviewNov 1, 2025
    Next Review DateMar 1, 2027
    Key ActionObtain prior authorization documenting a prepared wound bed, absence of active infection, objective perfusion assessment, evidence of optimized standard care, and product-label–consistent selection and duration.
    SourceLink
    On This Page
    Coverage Criteria for Skin SubstitutesRegulatory Identifiers, Codes, and Clinical ThresholdsPrior Authorization, Documentation, and Denial RisksClinical Background and RationaleDefinitions and Regulatory Terms
    Reassessment requirement:
    If continuing treatment beyond 4 weeks, wound area must have decreased by at least 50%; otherwise stop and reassess or consider alternate class.
    >=50% area reduction at 4 weeks

    Four-week reassessment rule applies to ulcers unless label specifies different timing.

    Regulatory tier preference: Prefer Tier 1 (PMA/BLA/HDE) products when clinically appropriate; if Tier 1 unsuitable, Tier 2 (510(k)) may be used; Tier 3 (361 HCT/P) are lowest priority.

    Provide rationale when selecting non-Tier 1 product.

    Response benchmark
    Failure to achieve >= 50% wound area reduction after 4 weeks of optimized, etiology-specific standard care justifies considering advanced therapy.
    Optimized standard care componentsSerial debridement, moisture balance, infection control, and etiology-specific measures (e.g., offloading for DFU; sustained compression for VLU).
    Reassessment timingReassess wound area at 4 weeks; continuation of therapy beyond 4 weeks requires >=50% area reduction unless product labeling specifies a different timing.
    Minimum wound duration before advanced therapy — product-specific minimums
    Apligraf (DFU)Minimum duration before advanced therapy per FDA label: at least 3 weeks.
    Dermagraft (DFU)Minimum duration before advanced therapy per FDA label: at least 6 weeks.
    Omnigraft (DFU)Minimum duration before advanced therapy per FDA label: at least 6 weeks.
    Venous leg ulcer (Apligraf)Minimum duration before advanced therapy: greater than 1 month with sustained therapeutic compression.
    • Indicate the specific FDA-labeled indication being requested and reference the appendix mapping.
    • Expect evaluation of product-to-wound alignment per the regulatory‑verified framework.
    Prior Authorization

    Document product selection, label match, and minimization of alternatives

    The prior authorization request must demonstrate that the selected product matches the FDA‑labeled indication and regulatory tier rationale, that the minimum wound duration per product labeling has been met, and that alternatives were minimized by documenting prior optimized care.

    • Show FDA-labeled indication match (etiology, depth, duration, anatomic limits, population).
    • Document minimum chronicity per label (e.g., Apligraf ≥3 weeks; Dermagraft/Omnigraft ≥6 weeks; VLU Apligraf >1 month).
    • Explain why a lower‑tier or alternative product is not appropriate when selecting a non‑preferred product.
    Step Therapy

    Require optimized standard care and objective response before advanced therapy

    Prior to escalation to a skin substitute, document optimized standard wound care including serial debridement, moisture balance, infection control, and etiology‑specific measures (effective offloading for DFU or sustained compression for VLU); assess objective response and apply the ≥50% area‑reduction benchmark at four weeks when continuing therapy.

    • Record serial debridement and measures to maintain moisture balance and control infection.
    • Document etiology‑specific care (e.g., offloading or sustained compression) that was ongoing during the observation period.
    • Use ≥50% area reduction at 4‑week reassessment as the response threshold to continue the same product.
    Note

    Follow appendix sequencing for product selection

    Select products in the sequence shown in the regulatory‑verified appendix: prefer FDA‑labeled Tier 1 products for the mapped wound characteristic, use Tier 2 only when no suitable Tier 1 exists, and consider Tier 3 only as lowest priority — follow the wound‑to‑product mapping in the appendix.

    • Follow the appendix wound‑to‑product mapping table for preferred product class per wound characteristic.
    • Adhere to the appendix when selecting alternative classes if Tier 1 products are unsuitable.
    Note

    Prefer Tier 1 products; tiered selection required

    When clinically appropriate, prefer Tier 1 products (PMA/BLA/HDE); use Tier 2 (510(k)) devices only if no suitable Tier 1 option exists; reserve Tier 3 (361 HCT/P) as the lowest priority and note they are not FDA‑approved for wound indications.

    • Tier 1 = PMA / BLA / HDE (preferred when label fits the wound).
    • Tier 2 = 510(k) cleared devices (use if no Tier 1 suitable).
    • Tier 3 = 361 HCT/P (limited use; lowest priority).
    Documentation Required

    Document wound bed preparation, infection status, perfusion, and comorbidity management

    For medical necessity, include documentation of wound bed preparation (debridement), absence of active infection, objective perfusion measures supporting healing potential, and evidence that comorbidities and etiology‑specific interventions (offloading or compression) are being managed.

    • Document evidence of adequate debridement and moisture balance.
    • Record perfusion assessment findings (toe pressure, TcPO2, or SPP as applicable).
    • Confirm management of comorbidities and etiology‑specific interventions (offloading/compression).
    Documentation Required

    Record wound type, indication, and prior conservative care

    Document wound type, the specific indication for the skin substitute (DFU, VLU, or thermal burn), and evidence of prior conservative care consistent with guidelines and the policy (e.g., duration and components of optimized care).

    • State wound etiology (diabetic foot ulcer, venous leg ulcer, or thermal burn) and clinical history.
    • Provide records of prior conservative care and guideline‑consistent measures undertaken.
    Documentation Required

    Include product‑specific minimum duration and foundational care documentation

    Provide supporting documentation of wound duration meeting product‑specific minimums and evidence of optimized foundational care: e.g., Apligraf DFU ≥3 weeks; Dermagraft/Omnigraft DFU ≥6 weeks; VLU with Apligraf >1 month (with sustained compression). Also include perfusion status, debridement, moisture balance, and infection control notes.

    • Minimum duration per label: Apligraf (≥3 weeks for DFU); Dermagraft/Omnigraft (≥6 weeks for DFU); VLU Apligraf (>1 month with compression).
    • Include objective perfusion data, debridement records, and infection control documentation.
    Documentation Required

    Provide FDA‑label alignment and tier justification for non‑preferred products

    When requesting a non‑preferred or lower‑tier product, document the FDA‑labeled indication match for the chosen product (etiology, depth, duration, anatomic limits, population) and provide the clinical rationale for selecting a non‑Tier 1 product.

    • Cite the exact FDA label elements that match the patient’s wound.
    • Explain why a Tier 1 product was unsuitable and justify the chosen tier.
    Denial Risk

    Common denial triggers and investigational exclusions to avoid

    Common denial triggers include lack of documented offloading for DFU or sustained compression for VLU, uncontrolled infection or untreated ischemia below defined thresholds, an unprepared wound bed, known hypersensitivity to the product source, routine use for pressure ulcers, prophylactic/cosmetic uses, use on fully epithelialized wounds, simultaneous use of more than one product, and continuation when <50% area reduction after 4 weeks of product use.

    • Missing documented offloading (DFU) or sustained compression (VLU).
    • Uncontrolled infection, untreated ischemia, or unprepared wound bed.
    • Simultaneous use of multiple products or continuation despite <50% area reduction at 4 weeks.
    Note

    Coverage requires alignment with FDA labeling and payer decision rules

    Coverage decisions align product use with FDA labeling and the payer’s decision rules; failure to follow FDA‑labeled indications or the regulatory‑verified framework may result in denial of coverage.

    • Ensure product use matches the exact FDA‑labeled indication (etiology, depth, duration, anatomy, population).
    • Reference the regulatory‑verified appendix when submitting requests.
    Denial Risk

    Deep‑structure exposure excludes most listed products unless label permits

    Ulcers with exposed tendon, muscle, joint capsule, or bone are not eligible for listed skin substitute products unless the product labeling explicitly permits such use; surgical optimization and infection control (including consideration of grafting/autograft) should be addressed first.

    • Do not use listed skin substitutes on wounds with exposed deep structures unless the product label explicitly allows it.
    • Optimize surgical coverage and control infection before considering advanced skin substitutes.
    Denial Risk

    Document optimized standard care and minimum duration to avoid denial

    Failure to document that optimized standard care was provided for diabetic foot ulcers and venous leg ulcers for the required minimum duration (generally four weeks unless the FDA label specifies a longer period) may lead to denial.

    • Document the components and duration of optimized standard care (serial debridement, moisture balance, infection control, offloading/compression).
    • If the FDA label requires a longer pre‑treatment duration, document compliance with that label.
    Denial Risk

    Document ≥50% area reduction at 4‑week reassessment to continue therapy

    If continuing skin substitute therapy beyond four weeks, document a ≥50% reduction in wound area at the 4‑week reassessment; failure to demonstrate this objective improvement is a common reason for denial and requires stopping and reassessing therapy.

    • Use the four‑week reassessment rule: continue only if wound area decreased by at least 50%.
    • If <50% reduction at 4 weeks, stop, reassess, and consider an alternative class or intervention.
    Wound should be clean and moisture-balanced as part of a prepared wound bed.
    Infection controlNo clinical signs of active infection and no untreated osteomyelitis at the ulcer site before application.
    Etiology-specific managementDocumented management such as proven offloading for DFU or sustained compression for VLU must be in place during treatment.
    Cellular vs acellular substitutes — brief distinction
    Primary distinctionCellular products contain living cells or cell-derived components; acellular products are decellularized matrices or membranes without live cells.
    Clinical implicationsComparative trials show varied outcomes without a uniform advantage for either category; selection is context-dependent and should align with labeling.
    Typical functionsCellular products may provide cellular activity and growth factors; acellular products mainly provide scaffold and biologic matrix support.
    Regulatory-verified framework — appendix-based guide tying product selection to FDA labeling
    PurposeAn appendix-based guide to align product selection and continuation with FDA labeling to standardize payer coverage decisions for DFU, VLU, and thermal burns.
    Decision rule requirementProduct selection must match FDA-labeled indication (etiology, depth, duration, anatomic limits, population) as documented in the appendix.
    Tier alignmentThe framework maps products to regulatory tiers (Tier 1/2/3) to inform preferred sequencing and justification for non-Tier 1 selections.
    Tier 1 — PMA/BLA/HDE products with labeled wound indications
    DefinitionTier 1: FDA Premarket Approval (PMA), Biologics License Application (BLA), or Humanitarian Device Exemption (HDE) products with labeled wound indications.
    Preferred usePrefer Tier 1 products when clinically appropriate and when labeling matches the patient's wound characteristics.
    Examples referencedApligraf, Dermagraft, and Omnigraft are listed as Tier 1 products for specific diabetic foot ulcer indications in the product table.
    Tier 2 — 510(k) devices cleared for wound management indications
    DefinitionTier 2: 510(k) devices cleared for wound management indications based on substantial equivalence.
    When to useUse Tier 2 devices when no suitable Tier 1 product exists or when labeling and clinical context support their use.
    Examples referencedProducts such as OASIS and other 510(k)-cleared matrices are included in the product summary table under device clearances.
    Tier 3 — 361 HCT/P products without FDA wound-etiology approval
    DefinitionTier 3: Human cells, tissues, and cellular and tissue-based products regulated under section 361 without FDA wound‑etiology approval.
    Coverage priorityTier 3 products are lowest priority for selection under the regulatory‑verified framework and require rationale if chosen over higher tiers.
    Typical sourcesIncludes minimally manipulated human tissue-based products and biologic scaffolds that lack specific FDA wound indications.